Trade Assembly Biosciences, Inc. - ASMB CFD
Add to favourite- Summary
- Historical Data
Spread | 0.1722 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 15.6189 |
Open | 15.6689 |
1-Year Change | 1980.86% |
Day's Range | 14.9589 - 15.9989 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 20, 2024 | 15.1189 | -0.3900 | -2.51% | 15.5089 | 16.0089 | 14.8489 |
Dec 19, 2024 | 15.6189 | -0.2400 | -1.51% | 15.8589 | 16.4789 | 14.7089 |
Dec 18, 2024 | 13.4689 | -1.4900 | -9.96% | 14.9589 | 14.9689 | 13.0889 |
Dec 17, 2024 | 14.1789 | -0.4800 | -3.27% | 14.6589 | 15.1089 | 14.0989 |
Dec 16, 2024 | 15.2089 | 0.2400 | 1.60% | 14.9689 | 15.7589 | 14.8389 |
Dec 13, 2024 | 15.2089 | 0.2500 | 1.67% | 14.9589 | 15.3589 | 14.9289 |
Dec 12, 2024 | 15.0689 | -0.0900 | -0.59% | 15.1589 | 15.2089 | 14.8589 |
Dec 11, 2024 | 14.9789 | -0.7300 | -4.65% | 15.7089 | 15.7089 | 14.4989 |
Dec 10, 2024 | 15.8189 | -0.1600 | -1.00% | 15.9789 | 16.4589 | 15.7089 |
Dec 9, 2024 | 16.4289 | 0.6400 | 4.05% | 15.7889 | 16.9489 | 15.7889 |
Dec 6, 2024 | 16.0089 | -0.2100 | -1.29% | 16.2189 | 16.4089 | 15.6989 |
Dec 5, 2024 | 16.0989 | 0.1400 | 0.88% | 15.9589 | 16.3789 | 15.9589 |
Dec 4, 2024 | 16.2289 | -0.2100 | -1.28% | 16.4389 | 16.4389 | 15.9189 |
Dec 3, 2024 | 16.1989 | -0.3700 | -2.23% | 16.5689 | 16.5689 | 15.4589 |
Dec 2, 2024 | 16.6689 | -0.3400 | -2.00% | 17.0089 | 17.2089 | 16.4589 |
Nov 29, 2024 | 16.9889 | 0.4800 | 2.91% | 16.5089 | 17.1589 | 16.5089 |
Nov 27, 2024 | 16.2889 | 1.1100 | 7.31% | 15.1789 | 16.6789 | 15.1689 |
Nov 26, 2024 | 14.9989 | -0.1900 | -1.25% | 15.1889 | 15.4689 | 14.7589 |
Nov 25, 2024 | 14.7689 | -0.1000 | -0.67% | 14.8689 | 15.4789 | 14.6389 |
Nov 22, 2024 | 14.9689 | 0.2900 | 1.98% | 14.6789 | 15.1189 | 14.3489 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Assembly Biosciences, Inc. Company profile
About Assembly Biosciences Inc
Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Assembly Biosciences Inc revenues decreased 92% to $6.3M. Net loss increased from $62.2M to $129.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest and other income, net decrease of 88% to $302K (income), Restructuring Charges & Provisions increase of 40% to $277K (expense).
Equity composition
Common Stock $0.001 Par, 4/11, 25M auth., 7,189,706 issd.insider control 7.88%. 07-14, 1-for-5 reverse stock split.
Industry: | Proprietary & Advanced Pharmaceuticals |
Two Tower Place
7Th Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com